MUELLER ON PATENT LAW

Volume I: Patentability and Validity

Janice M. Mueller
Patent Attorney and Co-Founder
Chisum Patent Academy
Professor of Law at University of Pittsburgh (2004–2011),
and Suffolk University (1996–1999)
# Summary of Contents

Table of Contents  

About the Author  

Preface  

Chapter 1  BASIC PRINCIPLES  

Chapter 2  PATENT CLAIMS  

Chapter 3  PATENT-ELIGIBLE SUBJECT MATTER  

Chapter 4  THE ENABLEMENT REQUIREMENT  

Chapter 5  THE BEST MODE REQUIREMENT  

Chapter 6  THE WRITTEN DESCRIPTION OF THE INVENTION REQUIREMENT  

Chapter 7  NOVELTY, NO LOSS OF RIGHT, AND PRIORITY [PRE-AMERICA INVENTS ACT OF 2011]  

Chapter 7A  NOVELTY, NO LOSS OF RIGHT, AND PRIORITY [POST-AMERICA INVENTS ACT OF 2011]  

Chapter 8  INVENTORSHIP  

Chapter 9  THE NONOBVIOUSNESS REQUIREMENT  

Chapter 10  THE UTILITY REQUIREMENT  

Chapter 11  PATENT PROSECUTION PROCEDURES IN THE U.S. PATENT AND TRADEMARK OFFICE  

Chapter 12  DOUBLE PATENTING  

Glossary  

Table of Cases  

Table of Authorities  

v Last revised July 2019
<table>
<thead>
<tr>
<th>CONTENTS</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table of Statutes</td>
<td>1213</td>
</tr>
<tr>
<td>Index</td>
<td>1233</td>
</tr>
</tbody>
</table>
# Table of Contents

About the Author  xxv
Preface  xxvii

<table>
<thead>
<tr>
<th>Chapter 1</th>
<th>BASIC PRINCIPLES</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>§1.01</td>
<td>Patents in Context</td>
<td>2</td>
</tr>
<tr>
<td>[A]</td>
<td>Introduction</td>
<td>2</td>
</tr>
<tr>
<td>[B]</td>
<td>Patents as Strategic Business Assets</td>
<td>3</td>
</tr>
<tr>
<td>[C]</td>
<td>Patents and Global Trade</td>
<td>6</td>
</tr>
<tr>
<td>[D]</td>
<td>Patents and the Public Interest</td>
<td>7</td>
</tr>
<tr>
<td>[E]</td>
<td>Patents as a Form of Intellectual Property Protection</td>
<td>8</td>
</tr>
<tr>
<td>[3]</td>
<td>Intellectual Property Rights as an Exception to the General Rule of Competition by Imitation</td>
<td>10</td>
</tr>
<tr>
<td>§1.02</td>
<td>The Right to Exclude Conveyed by a Patent</td>
<td>11</td>
</tr>
<tr>
<td>[A]</td>
<td>Negative, Not Positive, Right</td>
<td>11</td>
</tr>
<tr>
<td>[B]</td>
<td>Blocking Patents</td>
<td>12</td>
</tr>
<tr>
<td>§1.03</td>
<td>Policy Justifications for Patent Protection</td>
<td>14</td>
</tr>
<tr>
<td>[A]</td>
<td>Natural Rights</td>
<td>14</td>
</tr>
<tr>
<td>[B]</td>
<td>Reward for Services Rendered</td>
<td>15</td>
</tr>
<tr>
<td>[C]</td>
<td>Monopoly Profits Incentive</td>
<td>15</td>
</tr>
<tr>
<td>[D]</td>
<td>Exchange for Secrets</td>
<td>16</td>
</tr>
<tr>
<td>§1.04</td>
<td>Economics of the Patent System</td>
<td>17</td>
</tr>
<tr>
<td>[A]</td>
<td>Patent Ownership Versus Monopoly Power</td>
<td>17</td>
</tr>
<tr>
<td>[B]</td>
<td>Cost/Benefit Analysis</td>
<td>19</td>
</tr>
<tr>
<td>[1]</td>
<td>Costs</td>
<td>19</td>
</tr>
<tr>
<td>§1.05</td>
<td>The Term of a Patent</td>
<td>25</td>
</tr>
<tr>
<td>[A]</td>
<td>Length of Term</td>
<td>25</td>
</tr>
<tr>
<td>[B]</td>
<td>Patent Term Adjustment</td>
<td>27</td>
</tr>
<tr>
<td>§1.06</td>
<td>Sources of U.S. Patent Law</td>
<td>29</td>
</tr>
<tr>
<td>[A]</td>
<td>The Constitution</td>
<td>29</td>
</tr>
<tr>
<td>[B]</td>
<td>Federal Statutes and Regulations</td>
<td>31</td>
</tr>
<tr>
<td>[C]</td>
<td>Case Law</td>
<td>33</td>
</tr>
</tbody>
</table>
§1.07 Government Entities in the Patent System

[A] The U.S. Patent and Trademark Office 34

[B] U.S. Federal Courts 38

[1] U.S. District Courts 38

[a] Eastern District of Virginia 40


[3] U.S. Supreme Court 47


Chapter 2 PATENT CLAIMS 53

§2.01 Introduction 55


[C] Definition of a Patent Claim 56

[D] Public Notice Function 58

[E] Peripherial Versus Central Claiming 61


[1] “Own Lexicographer” Rule 62


§2.02 Components of Patent Claims 72

[A] Preamble 73

[1] Introduction 73

[2] Preamble Language as Claim Limiting 73

[B] Transition 77

[1] “Comprising” 77


[4] Other Transition Terminology 82

[C] Body 83

§2.03 Dependent Patent Claims 85

[A] Statutory Basis: 35 U.S.C. §§112(c)-(e) 86

[B] Claim Groupings 86

[C] Multiple Dependent Claims 87

[D] Claim Differentiation Principle 88

§2.04 Claim Definiteness Requirement 91

[A] Statutory Basis: 35 U.S.C. §112(b) 91

[B] Perspective for Determining Claim Definiteness 92

[D] Representative Examples of Definite and Indefinite Claim Terms 104

[1] Representative Examples of Definite Claim Terms 104
   [a] Orthokinetics (1986) 104
   [b] Verve, LLC (2002) 105
   [c] Young (2007) 106
   [e] Nautilus III (2014) 107
   [f] Sonix (2017) 109
   [g] One-E Way (2017) 113

[2] Representative Examples of Indefinite Claim Terms 116
   [a] Datamize (2005) 116
   [b] Interval Licensing (2014) 119
   [d] Dow Chemical II (2015) 123

[E] Judicial Correction of Harmless Errors in Claims 128
[F] Use of Antecedent Basis in Patent Claims 132
[G] Indefiniteness Standard in the USPTO 133

§2.05 Specialized Claiming Formats 137

[A] Means-Plus-Function Claims 137
   [1] Functional Claiming Generally 137
      [a] Scope-Narrowing 140
      [b] Corresponding Structure 141
      [c] Algorithms for Computer Structures 142
      [d] “Equivalents Thereof” 143
      [a] Claim Elements Including the Word “Means” 144
      [b] Claim Elements Not Including the Word “Means” 147

[B] Product-by-Process Claims 154
[C] Jepson Claims 160
[D] Markush Claims 163
[E] Beauregard Claims 166

Chapter 3 PATENT-ELIGIBLE SUBJECT MATTER 173

§3.01 Introduction 175
[B] The Statutory Categories Within §101 177
[C] Claiming the Inventive Concept Within the Statutory Categories 178

[D] Exceptions to §101 179

§3.02 Processes Within §101 181

[A] Definition of a Process 181

[B] Process Versus Product 182


[D] Business Methods and the “Abstract Idea” Exception 185

[1] Overview 185


[a] In re Bilski (Fed. Cir. 2008) (en banc) 191


[i] Step One—Claims Directed to Abstract Idea or Law of Nature? 201

[ii] Step Two—Inventive Concept? 201

[d] Alice Corp. v. CLS Bank (U.S. 2014) 202

[i] Step One—Claims Directed to Abstract Idea or Law of Nature? 204

[ii] Step Two—Inventive Concept? 205


[i] Introduction 208

[ii] Post-Alice Decisions Holding Inventions Patent-Ineligible 210

[iii] Does Mayo/Alice Step Two Involve Questions of Fact? 215


[a] DDR Holdings (2014) 226

[b] Enfish (2016) 229


[d] Bascom (2016) 238

[e] Amdocs II (2016) 242


[g] Visual Memory (2017) 250
<table>
<thead>
<tr>
<th>§3.03</th>
<th>Machines Within §101</th>
</tr>
</thead>
<tbody>
<tr>
<td>[A]</td>
<td>Definition of a Machine</td>
</tr>
<tr>
<td>[B]</td>
<td>Computer-Implemented Machines</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>§3.04</th>
<th>Compositions of Matter Within §101</th>
</tr>
</thead>
<tbody>
<tr>
<td>[A]</td>
<td>Definition of a Composition of Matter</td>
</tr>
<tr>
<td>[B]</td>
<td>Structure Versus Properties: Newly Discovered Properties of Known Compositions</td>
</tr>
<tr>
<td>[C]</td>
<td>Products of Nature</td>
</tr>
<tr>
<td>[1]</td>
<td>Purified Forms of Natural Products</td>
</tr>
<tr>
<td>[a]</td>
<td>Ass’n for Molecular Pathology v. Myriad Genetics (U.S. 2013)</td>
</tr>
<tr>
<td>[D]</td>
<td>Spontaneously Generated Compositions</td>
</tr>
<tr>
<td>[E]</td>
<td>Life Forms</td>
</tr>
<tr>
<td>[3]</td>
<td>Clones</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>§3.05</th>
<th>Manufactures Within §101</th>
</tr>
</thead>
<tbody>
<tr>
<td>[A]</td>
<td>Definition of a Manufacture</td>
</tr>
<tr>
<td>[B]</td>
<td>Embedded Software</td>
</tr>
<tr>
<td>[C]</td>
<td>Electrical Signals</td>
</tr>
</tbody>
</table>

Last revised July 2019
§3.06 Non-Eligible Subject Matter
§3.07 Remedies Exclusion for Medical/Surgical Procedures

Chapter 4  THE ENABLEMENT REQUIREMENT  325
§4.01 Introduction 325
[A] The Disclosure Requirements of 35 U.S.C. §112(a) 325
[B] Bargain/Exchange Theory 327
[C] Enabling “How to Make” and “How to Use” 328
[D] Filing Date as Measure of Disclosure Compliance/
    New Matter Prohibition 329
    [1] Incorporation by Reference 331
    [2] Biological Deposits 332
        Nonobviousness 333
§4.02 Undue Experimentation 334
[A] Wands Factors Framework 334
[B] Predictability of the Technology 338
    [1] Generally Predictable Technologies 338
    [3] Exceptions to General Rule 342
[C] Scope of Enabling Disclosure Versus Scope of the Claims 343
    [1] “Reasonable Correlation” Standard 343
[D] Use of Working and Prophetic Examples 353
    [1] Types of Examples 353
§4.03 Nascent and After-Arising Technology 356

Chapter 5  THE BEST MODE REQUIREMENT  359
§5.01 2011 Legislative Scale-Back of the Best Mode Requirement 359
§5.02 Best Mode as Enablement-Plus 361
§5.03 Unclear Policy Objectives 362
§5.04 No Best Mode Obligation in Many Foreign Countries 363
§5.05 Best Mode Compliance and Foreign Priority Claims 364
§5.06 Two-Step Analysis 367
[A] Step One: Subjective Inquiry 367

Last revised July 2019
TABLE OF CONTENTS

[B] Step Two: Objective Inquiry 370
  [1] Integrating Enablement with Best Mode 370
  [3] Production Details and Routine Details 372
§5.07 Scope of the Best Mode Disclosure Versus Scope of the Claims 377

Chapter 6 THE WRITTEN DESCRIPTION OF THE INVENTION REQUIREMENT 381
§6.01 The Varied Meanings of “Written Description” 381
§6.02 Priority Policing Mechanism 384
§6.03 Policy Rationale 386
§6.04 “Inventor in Possession” Test
  [B] Ambiguity in the Possession Test 398
§6.05 Written Description Versus Enablement 400
§6.06 Traditional “Time Gap” Situations Invoking Written Description Scrutiny 404
§6.07 Federal Circuit’s Expansion of the Written Description Requirement 413
§6.08 Conclusion 448

Chapter 7 NOVELTY, NO LOSS OF RIGHT, AND PRIORITY [PRE-AMERICA INVENTS ACT OF 2011] 449
Chapter Explanatory Note 453
  [A] Burden of Proof on USPTO 454
  [B] Claim Interpretation in USPTO 457
  [C] Prior Art as Defined by §102 458
  [D] Lack of Novelty Versus Loss of Right 459
  [E] Persons Who Can Trigger the §102 Provisions 461

Last revised July 2019
<table>
<thead>
<tr>
<th>§7.02 Anticipation</th>
<th>464</th>
</tr>
</thead>
<tbody>
<tr>
<td>[A] Definition</td>
<td>464</td>
</tr>
<tr>
<td>[B] Strict Identity Rule</td>
<td>464</td>
</tr>
<tr>
<td>1. “Four Corners”/Single Reference Rule</td>
<td>465</td>
</tr>
<tr>
<td>2. “Arranged as in the Claim”</td>
<td>465</td>
</tr>
<tr>
<td>[a] Generally</td>
<td>465</td>
</tr>
<tr>
<td>[b] Reference Not Anticipatory If It Must Be Distorted</td>
<td>467</td>
</tr>
<tr>
<td>3. Exceptions to the Single Reference/“Four Corners” Rule</td>
<td>472</td>
</tr>
<tr>
<td>4. No Analogous Art Requirement for Anticipation</td>
<td>473</td>
</tr>
<tr>
<td>5. To “Suggest” Is Not Sufficient for Anticipation</td>
<td>474</td>
</tr>
<tr>
<td>[C] Species/Genus Relationships</td>
<td>476</td>
</tr>
<tr>
<td>[D] Question of Fact</td>
<td>483</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>§7.03 Inherent Anticipation</th>
<th>484</th>
</tr>
</thead>
<tbody>
<tr>
<td>[A] Generally</td>
<td>484</td>
</tr>
<tr>
<td>1. “Necessarily Present”</td>
<td>484</td>
</tr>
<tr>
<td>2. Reference Failing to “Necessarily Disclose”</td>
<td>485</td>
</tr>
<tr>
<td>3. Use of Extrinsic Evidence to Establish Inherency</td>
<td>487</td>
</tr>
<tr>
<td>[B] Accidental Anticipation</td>
<td>491</td>
</tr>
<tr>
<td>[C] Contemporaneous Recognition Not Required</td>
<td>492</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>§7.04 Enablement Standard for Anticipatory Prior Art</th>
<th>493</th>
</tr>
</thead>
<tbody>
<tr>
<td>[A] General Principle</td>
<td>493</td>
</tr>
<tr>
<td>[B] Exception for Prior Art Compounds Lacking a Utility</td>
<td>494</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>§7.05 Anticipation Under §102(a)</th>
<th>496</th>
</tr>
</thead>
<tbody>
<tr>
<td>[A] Filing Date as Prima Facie Invention Date</td>
<td>496</td>
</tr>
<tr>
<td>1. References Having Effective Date Less Than One Year Before Applicant’s Filing Date</td>
<td>497</td>
</tr>
<tr>
<td>2. Antedating a Putative Prima Facie §102(a) Reference by Establishing an Earlier Invention Date</td>
<td>498</td>
</tr>
<tr>
<td>[a] Generally</td>
<td>498</td>
</tr>
<tr>
<td>[c] Disclaiming Affidavits</td>
<td>501</td>
</tr>
<tr>
<td>[B] “Known or Used by Others” Under §102(a)</td>
<td>501</td>
</tr>
<tr>
<td>[C] “Patented” Under §102(a)</td>
<td>506</td>
</tr>
<tr>
<td>[D] “Printed Publication” Under §102(a)</td>
<td>508</td>
</tr>
<tr>
<td>[E] Strategies for Overcoming a §102(a) Anticipation Rejection</td>
<td>508</td>
</tr>
</tbody>
</table>
§7.06 Loss of Right/Statutory Bars Under §102(b) 510

[A] Introduction 510

[1] Filing Date 511
[2] “Critical Date” 512

[B] Grace Period 513

[C] Policies Underlying the §102(b) Bars 514

[D] “Patented” Under §102(b) 515

[E] “Printed Publication” Under §102(b) 515

[1] Public Accessibility 516


[3] Confidentiality Norms 518

[4] Scientific or Technical Presentations 519

[5] Internet Postings 524
   [b] In re Lister (2009) 525

[6] Trade Shows and Conventions 530
   [a] GoPro (2018) 530
   [b] Nobel Biocare (2018) 531

[F] “Public Use” Bar of §102(b) 534


[2] Public Use by Third Parties 540
   [a] Generally 540
   [b] Corroboration of Oral Testimony 541

[3] Non-Public “Public Use” 544

[4] Ready for Patenting 546

[G] “On Sale” Bar of §102(b) 553

[1] Introduction 553

[2] Policy Considerations 553


   [a] Decisions Finding No Commercial Offer 559
   [b] Decisions Finding Commercial Offer 562
   [c] Supplier Sales 565
   [d] Contingent Sales (Conditions Precedent) 574
### TABLE OF CONTENTS

- **[5]** Post-\textit{Pfaff} Decisions Interpreting “Ready for Patenting” 579  
  - [a] Inventions Not Ready for Patenting 579  
  - [b] Inventions Ready for Patenting 581  
- **[H]** Experimental Use Negation of the Statutory Bars 585  
    - [a] “Negation” Not “Exception” 585  
    - [b] Assigning Burdens of Production and Proof 587  
- **[3]** Experimental Use Factors 590  
- **[4]** Must Experimental Use End with Actual Reduction to Practice? 594  
- **[5]** Positioning Experimental Use Within the \textit{Pfaff} Framework 596  
- **[I]** Cannot Antedate a §102(b) Reference 598  
- **[J]** Cannot Rely on Paris Convention Foreign Priority Date to Remove a §102(b) Reference 598  

#### §7.07 Abandonment Under §102(c) 599

#### §7.08 Foreign Patenting Bar of §102(d) 601  
  - [A] Policy Basis Underlying the §102(d) Bar 601  
  - [B] Two Prongs of §102(d) 602  
  - [C] Meaning of “Patented” in §102(d) 603

#### §7.09 Description in Another’s Earlier-Filed Published Application or Patent Under 35 U.S.C. §102(e) 604  
  - [A] Foundation: \textit{Milburn v. Davis-Bournonville} (U.S. 1926) 605  
  - [B] Reference Patent or Application Claims Same Invention 607  
  - [C] Ameliorating the “Secret Prior Art” Problem of §102(e) 608  
    - [1] Issued U.S. Patent as §102(e) Prior Art 608  
    - [2] Published U.S. Patent Application as §102(e) Prior Art 609  
    - [3] Published Patent Cooperation Treaty Application as §102(e) Prior Art 609  
  - [D] Effective Date of §102(e) Prior Art 610  
    - [1] Earliest U.S. Filing Date 610  
    - [2] Reference’s Foreign Priority Date Is Not Applicable (\textit{Hilmer} Rule) 611  
  - [E] Provisional §102(e) Rejections 611  
  - [F] Strategies for Overcoming a §102(e) Rejection 612  
    - [1] Generally 612  
    - [2] Corroboration for Declarations 612  

Last revised July 2019
<table>
<thead>
<tr>
<th>§7.10</th>
<th>Originality Requirement and Derivation Under §102(f)</th>
<th>619</th>
</tr>
</thead>
<tbody>
<tr>
<td>[A]</td>
<td>Originality</td>
<td>619</td>
</tr>
<tr>
<td>[B]</td>
<td>Derivation</td>
<td>620</td>
</tr>
<tr>
<td>[C]</td>
<td>Qualifying as an Inventor</td>
<td>620</td>
</tr>
<tr>
<td>[D]</td>
<td>Correcting Inventorship</td>
<td>621</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>§7.11</th>
<th>Prior Invention Under §102(g)</th>
<th>621</th>
</tr>
</thead>
<tbody>
<tr>
<td>[B]</td>
<td>The First-to-Invent Priority Rule</td>
<td>622</td>
</tr>
<tr>
<td>[1]</td>
<td>Statement of the Priority Rule</td>
<td>622</td>
</tr>
<tr>
<td>[2]</td>
<td>Reduction to Practice</td>
<td>623</td>
</tr>
<tr>
<td>[a]</td>
<td>Actual Reduction to Practice</td>
<td>623</td>
</tr>
<tr>
<td>[b]</td>
<td>Constructive Reduction to Practice</td>
<td>626</td>
</tr>
<tr>
<td>[4]</td>
<td>Conception</td>
<td>629</td>
</tr>
</tbody>
</table>

| [C] Interference Proceedings Under §102(g) (1) | 635 |
| [1]   | burdens of Proof                | 635 |

| [D] Anticipation Under §102(g) (2) | 641 |
| [1]   | Introduction                    | 641 |
| [2]   | Prior “Making” by Another       | 643 |
| [3]   | “In This Country” Requirement   | 644 |
| [4]   | Inurement                       | 644 |

Chapter 7A NOVELTY, NO LOSS OF RIGHT, AND PRIORITY [POST-AMERICA INVENTS ACT OF 2011] 651

Chapter Explanatory Note 652

§7A.01 Statutory Text: Post-AIA 35 U.S.C. §102 656

§7A.02 Sense of Congress and Legislative History for Post-AIA 35 U.S.C. §102 658

§7A.03 Prior Art Under Post-AIA 35 U.S.C. §102(a) 659
| [A]   | Introduction                    | 659 |
| [B]   | What §3 of the AIA Retained    | 661 |
| [C]   | What §3 of the AIA Changed     | 662 |

Last revised July 2019
TABLE OF CONTENTS

[D] Presumptively Novelty-Destroying Events Under Post-AIA §102(a)(1) 666

[1] Invention “Patented, Described in a Printed Publication, or in Public Use, [or] On Sale” Before Effective Filing Date 666

[2] Invention “Otherwise Available to the Public” Before Effective Filing Date 668

   [a] Introduction 669
   [b] Must a Publicized Sale Disclose the Details of the Invention? 673

[E] Presumptively Novelty-Destroying Events Under Post-AIA §102(a)(2) 686

§7A.04 Novelty-Preserving Exceptions Under Post-AIA 35 U.S.C. §102(b) 689
   [A] Introduction 689
   [B] Post-AIA §102(b)(1): Shields Against Post-AIA §102(a)(1) Presumptively Novelty-Destroying Events 690
      [1] “(A)-Type” Exceptions 690
      [2] “(B)-Type” Exceptions 693
   [C] Post-AIA §102(b)(2): Shields Against Post-AIA §102(a)(2) Presumptively Novelty-Destroying Events 693
      [1] “(A)-Type” Exceptions 694
      [2] “(B)-Type” Exceptions 695

§7A.05 Effective Date for AIA §3 “First Inventor to File” Amendments 696
§7A.06 Common Ownership Under Joint Research Agreements 698

Chapter 8 INVENTORSHIP 701

§8.01 Originality Requirement 702
§8.02 The Process of Inventing 704
      [1] Conception 704
         [a] Definition 704
         [b] Scientific Certainty Not Required 708
         [c] Corroboration 709
         [d] Importance of Conception 710

Last revised July 2019
TABLE OF CONTENTS

[2] Reduction to Practice 710
  [a] Actual Reduction to Practice 711
  [b] Constructive Reduction to Practice 711
[B] The Reality 711

§8.03 Joint Inventors 712
[A] Statutory Basis 712
[B] Who Qualifies as a Joint Inventor?
  [1] Conception as the Touchstone 712
  [2] Quality of the Contribution 713
    [a] “Not Insignificant in Quality” 713
    [b] Contribution of an “Essential Element” 715
[C] Burden of Proof and Standard of Review 718
[D] Decisions Denying Joint Inventorship 718
[E] Decisions Finding Joint Inventorship 721
[F] The Impact of Joint Inventorship on Ownership 723

§8.04 Correction of Inventorship 726
[A] Correction of Inventorship in Pending Patent Applications 727
[B] Correction of Inventorship in Issued Patents 727
  [1] Section 256 Actions Generally 727
  [2] Standing Requirement for Section 256 Actions 729

§8.05 Derivation 732
[A] Derivation Defined 732
  [1] Generally 733
  [3] Derivation Requires Proving Earlier Conception of Entire Invention as Claimed 735
[C] Derivation-Related Proceedings in the USPTO 738

Chapter 9 THE NONOBVIOUSNESS REQUIREMENT 745

§9.01 Statutory Basis: 35 U.S.C. §103 747
§9.02 Historical Background 751
  [A] Hotchkiss v. Greenwood and the Elusive Requirement for “Invention” 751
  [B] The Hotchkiss “Ordinary Mechanic” 753
  [C] Replacing “Invention” with Nonobviousness 753

Last revised July 2019
  [a] Enactment of §103 754
  [b] “Shall Not Be Negated” 755
  [c] The “Person Having Ordinary Skill in the Art” 755
  [d] “Would Have Been” Obvious 756

  [a] Constitutionality of §103 758
  [b] Analytical Framework for Nonobviousness Determinations: Overview 758

§9.03 Graham Factor (1): Scope and Content of the Prior Art 759
  [A] Terminology 759
  [C] Section 102/Section 103 Overlap 761
    [1] In re Bass (CCPA 1973) 762
  [D] Analogous Art 768
    [1] Required for Obviousness Under §103 768
    [2] Test of In re Wood 769
    [3] Same Field of Endeavor 770
    [4] Same Problem Addressed 774
    [5] Not Required for Anticipation Under §102 778

§9.04 Graham Factor (2): Differences Between Claimed Invention and Prior Art 778

§9.05 Graham Factor (3): Level of Ordinary Skill in the Art 780

§9.06 Graham Factor (4): Secondary Considerations 783
  [A] Evidentiary Weight 784
    [1] Diverging Views 784
    [2] Versus Strength of Prima Facie Case 790
    [3] Need for Explicit Analysis 793
  [B] Nexus Requirement 794
    [1] Generally 794
    [2] Rebuttable Presumption of Nexus 795
TABLE OF CONTENTS

[C] Evidence of Commercial Success 803
  [1] Generally 803
  [2] Nexus Requirement for Commercial Success 806
[D] Evidence of Long-Felt but Unsolved Need 807
[E] Evidence of Failure of Others 809
[F] “Etc.” 811
  [1] Evidence of Copying 812
  [2] Evidence of Licensing 814
  [4] Evidence of Skepticism 819
[G] Potential Impact of Blocking Patents on Secondary Considerations Evidence 820

§9.07 Combining Prior Art Disclosures 825
[A] Teaching, Suggestion, or Motivation to Combine 825
[B] Reasonable Expectation of Success 828
  [1] Degree of “Reasonableness” 829
[C] “Obvious to Try” (Pre-KSR Meaning) 838
[D] Unexpected Results 839
  [1] Generally 839
  [3] Placement in Graham Framework 848
[E] Teaching Away 848
  [1] Generally 848
  [3] Inoperability 850
  [5] Not Relevant to Anticipation 855

[A] Expanding the Reasons for Combining Prior Art Teachings 855
[B] Common Sense 860
[C] Requirement for Explicit Analysis 862
[D] Redefining “Obvious to Try” 865
[E] Predictability 871
[F] Representative Federal Circuit Applications of KSR 873
  [1] Mechanical Inventions 873
  [3] Pharmaceutical and Biotechnology Inventions 877
§9.09 The Prima Facie Case of Obviousness
[A] Generally 880
[B] In re Dillon (1990) (en banc) 883
[C] Burden-Shifting in Validity Litigation?
   [1] Cases Rejecting Burden-Shifting in Court Litigation 885
   [2] Cases Approving Burden-Shifting in Court Litigation 888
[D] Overlapping (or At Least Abutting) Ranges or Variables 899

§9.10 Federal Circuit’s Standards of Review in §103 Determinations 909
[A] USPTO 909
   [1] Factual Findings 909
[B] Federal District Court 911
   [1] Factual Findings by Court 912

§9.11 Biotechnological Processes: §103(b) (2006)
[Pre-America Invents Act of 2011] 912

Chapter 10 THE UTILITY REQUIREMENT 915
§10.01 Statutory Basis: 35 U.S.C. §101 915
§10.02 Practical/Real-World Utility 916
§10.03 Historical Development 919
   [A] Justice Story’s Standard 919
§10.04 Federal Circuit Examples 921
   [A] Chemical Compounds 921
   [B] Methods of Treating Disease 924
   [C] Genetic Inventions 927
§10.05 USPTO Examination Guidelines on Utility 929
§10.06 Inoperability 931
   [A] Examples of Inoperable Inventions 931
   [B] Inoperable Species Within a Genus 932
§10.07 Immoral or Deceptive Inventions 933
§10.08 Utility Versus How-to-Use Requirement of §112, ¶1 935

Chapter 11 PATENT PROSECUTION PROCEDURES IN
THE U.S. PATENT AND TRADEMARK OFFICE 937
§11.01 Introduction 938
§11.02 Filing the Patent Application 939
   [A] Non-Provisional/Regular Application 940
<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>§11.03</td>
<td>Examination by the USPTO</td>
<td>954</td>
</tr>
<tr>
<td>[A]</td>
<td>Overview</td>
<td>954</td>
</tr>
<tr>
<td>[B]</td>
<td>Search of Prior Art</td>
<td>955</td>
</tr>
<tr>
<td>[C]</td>
<td>First Office Action</td>
<td>956</td>
</tr>
<tr>
<td>[D]</td>
<td>Applicant’s Response</td>
<td>958</td>
</tr>
<tr>
<td>[E]</td>
<td>Second or Final Office Action</td>
<td>959</td>
</tr>
<tr>
<td>[F]</td>
<td>Requests for Continued Examination</td>
<td>960</td>
</tr>
<tr>
<td>[G]</td>
<td>Continuing Applications</td>
<td>961</td>
</tr>
<tr>
<td>§11.04</td>
<td>Patent Issuance</td>
<td>962</td>
</tr>
<tr>
<td>§11.05</td>
<td>Patent Term Adjustment</td>
<td>962</td>
</tr>
<tr>
<td>[A]</td>
<td>Generally</td>
<td>962</td>
</tr>
<tr>
<td>[B]</td>
<td>Overlap Limitation</td>
<td>964</td>
</tr>
<tr>
<td>[C]</td>
<td>Treatment of Continued Examination</td>
<td>967</td>
</tr>
<tr>
<td>[D]</td>
<td>What Constitutes USPTO Fault for A-Type Delay</td>
<td>968</td>
</tr>
<tr>
<td>§11.06</td>
<td>Publication of Pending Nonprovisional Applications</td>
<td>971</td>
</tr>
<tr>
<td>§11.07</td>
<td>Continuing Application Practice</td>
<td>973</td>
</tr>
<tr>
<td>[A]</td>
<td>Introduction</td>
<td>973</td>
</tr>
<tr>
<td>[B]</td>
<td>Three Types of Continuing Applications</td>
<td>975</td>
</tr>
<tr>
<td>[C]</td>
<td>Filing Requirements</td>
<td>976</td>
</tr>
<tr>
<td>[D]</td>
<td>Effective Filing Date of Claims in Continuing Applications</td>
<td>983</td>
</tr>
<tr>
<td>[E]</td>
<td>Patent Term of Continuing Applications</td>
<td>985</td>
</tr>
<tr>
<td>[F]</td>
<td>Divisional Applications</td>
<td>986</td>
</tr>
<tr>
<td>[1]</td>
<td>Restriction Requirements</td>
<td>986</td>
</tr>
<tr>
<td>[2]</td>
<td>Consonance Requirement</td>
<td>989</td>
</tr>
<tr>
<td>§11.08</td>
<td>Claiming Foreign Priority</td>
<td>991</td>
</tr>
<tr>
<td>[A]</td>
<td>Treaty Basis and Statutory Implementation</td>
<td>991</td>
</tr>
<tr>
<td>[B]</td>
<td>“Shall Have the Same Effect”</td>
<td>993</td>
</tr>
<tr>
<td>[C]</td>
<td>“Same Invention”</td>
<td>993</td>
</tr>
<tr>
<td>[D]</td>
<td>Formal Requirements</td>
<td>994</td>
</tr>
<tr>
<td>[E]</td>
<td>First-Filed Foreign Applications</td>
<td>995</td>
</tr>
<tr>
<td>§11.09</td>
<td>Appeals to the USPTO Patent Trial and Appeal Board</td>
<td>996</td>
</tr>
<tr>
<td>[A]</td>
<td>Generally</td>
<td>996</td>
</tr>
<tr>
<td>[B]</td>
<td>Challenging the Board’s Decision</td>
<td>998</td>
</tr>
<tr>
<td>[C]</td>
<td>New Ground of Rejection by Board</td>
<td>999</td>
</tr>
<tr>
<td>§11.10</td>
<td>Civil Actions for a Patent</td>
<td>1003</td>
</tr>
<tr>
<td>§11.11</td>
<td>Sample Office Action and Applicant’s Response</td>
<td>1006</td>
</tr>
<tr>
<td>§11.12</td>
<td>Sample Patent and Its Components</td>
<td>1011</td>
</tr>
</tbody>
</table>
Chapter 12  DOUBLE PATENTING  1017

§12.01  Introduction  1017

§12.02  Two Types of Double Patenting  1019
[A]  Same Invention-Type Double Patenting  1020
[B]  Obviousness-Type Double Patenting  1020

§12.03  Policy Bases  1021
[A]  Prevent Improper Extension of Patentee’s Right to Exclude Others  1021
[B]  Prevent Potential Harassment by Multiple Assignees  1022

§12.04  Foundational Case Study  1026

§12.05  Twenty-Year Patent Term Did Not Eliminate Double Patenting Concerns  1028

§12.06  How Double Patenting Differs from Anticipation and Obviousness  1031
[A]  Claim-to-Claim Comparison  1031
[B]  Prior Art Is Not Involved  1033
[C]  Similarities  1035

§12.07  Proper Use of the Disclosure to Interpret the Claims  1036

§12.08  Improper Use of the Disclosure as Prior Art  1037

§12.09  Use of Terminal Disclaimer to Overcome Obviousness-Type Double Patenting  1043
[A]  Terminal Disclaimers in the USPTO  1043
[B]  Terminal Disclaimers in Litigation  1046
[C]  Terminal Disclaimer Does Not Admit Claims Patentably Indistinct  1048

§12.10  One-Way Versus Two-Way Test for Obviousness-Type Double Patenting  1052

Glossary  1059
Table of Cases  1071
Table of Authorities  1187
Table of Statutes  1213
Index  1233
About the Author